EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) has agreed to sell Yutiq (fluocinolone acetonide intravitreal implant) 0.18mg to Alimera Sciences Inc (NASDAQ:ALIM). Yutiq is a treatment for chronic ...
ATLANTA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned ...
Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "YUTIQ Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The YUTIQ market report also covers patents, ...
CALM: 24-Month Safety Outcomes From a Real-World Registry Study of Patients with Chronic Non-infectious Uveitis Affecting the Posterior Segment Treated with the 0.18 mg Fluocinolone Acetonide ...
WATERTOWN, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, ...
– YUTIQ® CALM registry study collecting real-world data on patients with fluocinolone acetonide intravitreal (FAi) implant 0.18 mg is ongoing – WATERTOWN, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- ...
WATERTOWN, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In this Healio Video Perspective from the ASRS meeting, ...
(MENAFN- GlobeNewsWire - Nasdaq) Key market opportunities for YUTIQ stem from the growing need for long-term management of non-infectious posterior uveitis, its advantages in sustained drug delivery, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results